Inmune Bio (INMB) Times Interest Earned (2018 - 2026)
Inmune Bio (INMB) posted Times Interest Earned of -$22.44 for Q1 2026, down 123.42% sequentially from -$10.04 in Q4 2025, and down 2023.26% YoY from $1.17 in Q1 2025.
Inmune Bio (INMB) Times Interest Earned (2018 - 2026) Analysis & Trends
Inmune Bio has reported Times Interest Earned for 9 years, with the latest figure at -$22.44 in Q1 2026.
- Quarterly Times Interest Earned fell 2023.26% year-over-year to -$22.44 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$167.14 (down 3672.52% YoY) and the FY2025 annual result came in at -$1.37, up 17.75% from the prior year.
- Times Interest Earned eased to -$22.44 in Q1 2026 per INMB's latest filing, from -$10.04 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.01 in Q3 2022 and troughed at -$161.65 in Q2 2025.
- A 5-year average of -$16.42 and a median of -$9.2 in 2024 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned surged 95.59% in 2024, then plunged 17359.65% in 2025.
- Over 5 years, Times Interest Earned stood at -$6.58 in 2022, then tumbled by 43.98% to -$9.48 in 2023, then gained by 2.94% to -$9.2 in 2024, then declined by 9.17% to -$10.04 in 2025, then plunged by 123.42% to -$22.44 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$22.44, -$10.04, and -$6.18 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.91 |
| Mar 31, 2026 | -22.44 |
| Dec 31, 2025 | -10.04 |
| Sep 30, 2025 | -6.18 |
| Jun 30, 2025 | -161.65 |
| Mar 31, 2025 | -1.06 |
| Dec 31, 2024 | -9.20 |
| Sep 30, 2024 | -0.08 |
| Jun 30, 2024 | -0.93 |
| Mar 31, 2024 | -0.46 |
| Dec 31, 2023 | -9.48 |
| Sep 30, 2023 | -1.74 |
| Jun 30, 2023 | -10.16 |
| Mar 31, 2023 | -10.50 |
| Dec 31, 2022 | -6.58 |
| Sep 30, 2022 | -0.01 |
| Jun 30, 2022 | -13.74 |
| Mar 31, 2022 | -14.89 |
| Dec 31, 2021 | -20.57 |
| Sep 30, 2021 | -0.20 |